Brad Canino
Stock Analyst at Guggenheim
(3.58)
# 1,016
Out of 5,182 analysts
25
Total ratings
50%
Success rate
8.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $40 → $38 | $15.17 | +150.49% | 2 | Mar 17, 2026 | |
| RLAY Relay Therapeutics | Maintains: Buy | $15 → $22 | $12.45 | +76.71% | 2 | Mar 13, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $72 → $68 | $14.94 | +355.15% | 2 | Feb 27, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $14.92 | +101.07% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $19.38 | +80.60% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.50 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $103.71 | +49.46% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.45 | +382.76% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $85.27 | +5.55% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $18.69 | +114.02% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $67.55 | +33.23% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $114.22 | -3.69% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $8.91 | +102.02% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.84 | +181.69% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.49 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $25.84 | +112.85% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $43.98 | -31.79% | 2 | Mar 31, 2021 |
Olema Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $40 → $38
Current: $15.17
Upside: +150.49%
Relay Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $22
Current: $12.45
Upside: +76.71%
Janux Therapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $72 → $68
Current: $14.94
Upside: +355.15%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $14.92
Upside: +101.07%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $19.38
Upside: +80.60%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.50
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $103.71
Upside: +49.46%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.45
Upside: +382.76%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $85.27
Upside: +5.55%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $18.69
Upside: +114.02%
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $67.55
Upside: +33.23%
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $114.22
Upside: -3.69%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $8.91
Upside: +102.02%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.84
Upside: +181.69%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.49
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $25.84
Upside: +112.85%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $43.98
Upside: -31.79%